Professional Documents
Culture Documents
Pharmaceutical Preformulation
Wei-Qin (Tony) Tong, Ph.D.
Novartis Pharmaceuticals Corporation Integrated Drug Product Development Process (3 day-course), University of Utah July 17-19, 2006
Introduction
Preformulation:
l
a stage of development during which the physicochemical properties of drug substance are characterized Solubility Dissolution behavior Stability Partition coefficient Ionization constant (pKa) Solid state properties such as crystal forms/polymorphs, water sorption behavior, surface properties, particle size and shape, and other mechanical properties, et. al.
It is a capital mistake to theorize before one has data Scandal in Bohemia, Sir Arthur Conan Doyle
l
Learning before Doing Develop a knowledge base There are critical differences between companies at the detailed level of knowledge and their ability to learn before doing
knowledge of the underlying variables and their relationship to performance knowledge of the future manufacturing environment and the new variables introduced by that environment
Lead optimization
NDA
3 months to 6 months
6 months to 24 months
3 months to 9 months
12 months to 24months
Preformulation
Solubility
l
Background
Drug candidates are becoming more lipophilic and poorly soluble
A SURVEY OF 257 MARKETED DRUGS AND THEIR LIPOPHILICITY RECENT TRENDS IN DISCOVERY PIPELINE
All Drugs
CNS Drugs
Background
Recent trends in aqueous solubility of discovery compounds
50 40
Practically Insoluble
Percent
30 20 10 0
<10g/mL 10-100g/mL >100g/mL
Aqueous Solubility
l l l l l
Poor dissolution rate Low and variable bioavailability More potential for food effect Inability to deliver high doses for tox studies Difficulty in developing parenteral formulations
Dissolution
Systemic circulation
l Dependent
l Biopharmaceutical
Classification
10000
Solubility ( g/ml)
207 52 52
207
10
l Class
l l l
Boundaries
Highly soluble: the highest does is soluble in <250 ml water over a pH range of 1 to 7.5 Highly permeable: >90% dose absorbed in humans Rapidly dissolving: >85% of labeled amount of drug substance dissolves within 30 minutes
l Dissolution
The absolute amount of drug absorbed increases with the increasing of the dose Reduce particle size and using solution formulation should enhance absorption
l Solubility
limited absorption
The absolute amount of drug absorbed does not increase with the increasing of the dose Increasing dissolution rate does not increase absorption
l High
crystallinity/high MP
LogP
vs. crystalline
Examples
l Comparison
S. Yalkowsky, Solubility and Solubilization in Aqueous Media, American Chemical Society, Washington D.C. (1999).
l Comparison
S. Yalkowsky, Solubility and Solubilization in Aqueous Media, American Chemical Society, Washington D.C. (1999).
l Definition
Molarity of the substance in a solution that is at chemical equilibrium with an excess of the undissolved substance
l What
is kinetic/non-equilibrium solubility?
1.0
0.8
0.6
0.4
pKa'
0.2
0.0 1
pH
Effect of temperature
Solubility of Salts
l Challenges
pH of the saturated solution vs. pHmax It is only from a solubility experiment at a pH below pHmax that the solubility of the salt of a weak base can be estimated.
l Different
Dissolution
l
Importance of Dissolution
l l
Dissolution rate for poorly soluble compounds may often be the rate limiting step to absorption Examples of drugs with dissolution rate limited absorption: Digoxin Penicillin V Phenytoin Quinidine Tetracyclines
l l l
Volume of the dissolution medium: dose:solubility ratio Intrinsic dissolution rate constant: using rotating disk apparatus Surface area of the solid
particle size effect Effective surface area: the portion in actual contact with the dissolution medium
Higher dissolution rate in the gut for soluble salts Super-saturation possibility Importance of knowing the solubility of the HCl salt Potential negative impacts by salts: Higher degradation
Conversion to free base on the surface impact on the dissolution of the remaining salts Potential toxicity
l Effect
Stability
l Importance
of stability
l Theoretical
Chemical Stability
l l l
Excipient compatibility
Effect of moisture Effect of processing
Degradation mechanism
Hydrolysis Oxidation potential Effect of temperature
Physical Stability
l Characterization
of Amorphous Material
of hydrates/solvates
l Theoretical
(solubility/dissolution rate)
l Processing
Hygroscopicity Bulk, mechanical, and rheological properties Ease of isolation, filtration, and drying Degree of purification
Fundamental Question:
What will be the consequence should a new thermodynamically more stable form is discovered?
High risk if this could lead to significant delay in the overall project timeline or product failure Low risk if impact on timeline and resources are minimum
Poorly soluble compounds as defined by the FDA biopharmaceutical classification system: Solubility in pH 1-8 solutions x 250 mL < Dose Compounds that would require one of the nonequilibrium methods or semi-solid/liquid formulations to enhance dissolution rate/ bioavailability
amorphous meta-stable polymorphs solid dispersion lipid based formulations
Compounds with parenteral formulations formulated close to equilibrium solubilities at given temperature
Original API
PTR: Patent Term Restoration = half of the investigational period + all of the FDA review period
Balancing Various Factors: Physical stability: the thermodynamically most stable form is always the preferred choice Bioavailability: clinically relevant doses vs. tox coverage Process consideration Other physicochemical properties such as hygroscopicity, morphology and chemical stability
Toxicological Considerations
Suspensions
Final Thoughts
Thorough preformulation work is the foundation of developing robust formulations. Pay now or pay later is a balancing act. Organization structures vary, but the science doesnt. Good science is always the right thing to do!
Additional Reading
l l l l l l l l l l l l l
G. Banker and C.T. Rhodes, Modern Pharmaceutics, Marcel Dekker, Inc., 2000. H. Brittain, Physical Characterization of Pharmaceutical Solids, Marcel Dekker, Inc., 1995. H. Brittain, Polymorphism in Pharmaceutical Solids, Marcel Dekker, Inc., 1999. S.R. Byrn, R.R. Pfeiffer and J.G. Stowell, Solid State Chemistry of Drugs, Second Edition, SSCI, Inc., 1999. K.A. Connors, G.L. Amidon, and V.J. Stella. Chemical Stability of Pharmaceuticals (Second Edition), John Wiley & Sons, Inc., 1986. E.F. Fiese and T.A. Hagen, Preformulation, Chapter 8 in the Theory and Practice of Industrial Pharmacy, Lea & Febiger, Philadelphia, 1986. M. Gibson, Pharmaceutical Preformulation and Formulation, HIS Health Group, Englewood, CO, 2001. D.J.W. Grant and T. Higuchi, Solubility Behavior of Organic Compounds, John Wiley & Sons, Inc., 1990. L.F. Huang and W.Q. Tong, Impact of solid state properties on developability assessment of drug candidates, Advanced Drug Delivery Review, 56 (321-334), 2004. L.J. Ravin and G.W. Radebaugh, Preformulation, Chapter 75 in Remingtons Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pennsylvania, 1990. W.Q. Tong, Preformulation Aspects of Insoluble Compounds in Water Insoluble Drug Formulation, Edited by R. Liu, Interpharm Press, 2000. J. Wells, Pharmaceutical Preformulation, Ellis Horwood Limited, 1988. S. Yalkowsky, Solubility and Solubilization in Aqueous Media, American Chemical Society, Washington D.C. 1999.